Understanding AOD-9604: Isolating the Lipolytic Tail of Growth Hormone
Full-length human growth hormone (hGH) is a 191-amino-acid polypeptide secreted by the anterior pituitary gland. While hGH plays a well-known role in stimulating fat breakdown (lipolysis), administering full-length recombinant hGH activates the systemic growth hormone receptor, elevates hepatic insulin-like growth factor 1 (IGF-1), and can induce insulin resistance, fluid retention, and tissue overgrowth.
Biochemists investigating human growth hormone discovered that the fat-regulating activity of hGH resides in the final 16 amino acids of the molecule's carboxyl terminus (residues 176–191). By substituting a tyrosine residue at the N-terminal position of that fragment and preserving its internal disulfide bond, researchers created AOD-9604 (Tyr-hGH177–191)—a stabilized peptide designed to study adipocyte lipid metabolism independently of the growth-promoting domains of full-length hGH.
Because AOD-9604 lacks the structural regions required to bind the classical hGH receptor, preclinical and clinical investigations have focused on how it modulates lipid turnover without altering serum IGF-1 or glucose homeostasis.
How AOD-9604 Signals in Adipose Tissue: The Science Behind the Mechanism
Unlike central nervous system appetite suppressants or sympathomimetic stimulants, AOD-9604 has been studied for direct peripheral effects on adipocyte metabolism through three primary biochemical pathways:
1. Stimulating Lipolysis (Breakdown of Stored Triglycerides)
In rodent obesity models and isolated adipocyte assays, AOD-9604 increases lipolytic activity—the enzymatic cleavage of stored triglycerides into glycerol and free fatty acids that can be oxidized in mitochondria. Rather than acting as a central nervous system stimulant, the C-terminal hGH fragment stimulates lipid mobilization in adipose tissue by supporting hormone-sensitive lipase activity—the rate-limiting step in breaking down stored fat droplets inside adipocytes.
2. Inhibiting Lipogenesis (Reducing New Fatty Acid Synthesis)
In addition to mobilizing stored triglycerides, AOD-9604 has been shown in laboratory models to downregulate lipogenic enzyme activity—the pathway through which adipocytes convert excess dietary glucose into newly esterified triglycerides. Research indexed in the National Library of Medicine demonstrates that the C-terminal hGH region reduces lipogenic flux in adipose tissue, limiting fatty acid esterification in vitro.
3. Absence of Classical hGH Receptor Binding and IGF-1 Elevation
One of the defining characteristics of AOD-9604 in comparative endocrinology is its selectivity. In competitive binding assays, AOD-9604 does not compete with full-length somatotropin for the hGH receptor and does not trigger cell proliferation in hGH-dependent cell lines. Studies archived in PubMed Central confirm that unlike intact hGH, AOD-9604 does not induce hyperglycemia or impair insulin sensitivity during oral glucose tolerance testing.
What Clinical and Preclinical Studies Show
AOD-9604 has been evaluated in human safety and efficacy studies:
- Human Trials: Clinical studies documented via ClinicalTrials.gov evaluated AOD-9604 safety and efficacy and reported general tolerability with a low incidence of adverse events. These reports do not establish regulatory approval or long-term human safety.
- Comparison with Modern Metabolic Peptides: In contemporary weight-loss and metabolic peptide research, AOD-9604's modest clinical trial effect sizes contrast sharply with FDA-approved GLP-1 and GIP/GLP-1 receptor agonists, which act centrally on satiety and gastric emptying and have demonstrated substantial weight reduction in Phase III trials.
Safety Profile and Observations from Human Trials
Because AOD-9604 was evaluated in controlled human trials, its short-term tolerability profile is better documented than many purely preclinical peptides, though long-term human outcome data remain absent. For a broader framework on evaluating peptide evidence, read Are Peptides Safe?
Key Safety Findings in Clinical Literature
- Glucose Metabolism: Research reports no significant effect on glucose metabolism; this does not establish a treatment indication.
- Endocrine Effects: AOD-9604 is discussed as a fragment that differs from full-length growth hormone; human treatment conclusions require clinical evidence.
- Reported Adverse Events: Mild local reactions have been reported in clinical trials. Headache and temporary fatigue also appear in reports, while long-term human safety remains unestablished.
- Reproductive and Pediatric Evidence: Human safety during pregnancy, breastfeeding and childhood is not established.
U.S. Regulatory Status (FDA Bulk Drug Substances Update)
AOD-9604 is not approved by the U.S. Food and Drug Administration (FDA) as a prescription or over-the-counter drug for weight loss, osteoarthritis, or any other medical indication. While a separate food-ingredient notification once gave AOD-9604 conditional GRAS status strictly for limited oral food/beverage applications at micro-quantities, that notification never authorized injectable or therapeutic drug claims.
On the FDA Bulk Drug Substances lists current as of April 22, 2026, AOD-9604 is listed as nominated for Category 2, but withdrawn. Because it is neither a component of an FDA-approved drug nor on FDA's positive compounding list, routine 503A/503B pharmacy compounding of injectable AOD-9604 for human medical use is restricted. See our full breakdown in Do I Need a Prescription for Peptides?
In competitive athletics, the World Anti-Doping Agency (WADA) explicitly prohibits AOD-9604 and hGH fragments under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics).
Analytical Quality and Third-Party COA Verification
In laboratory research, a major technical variable with synthetic 16-amino-acid fragments like AOD-9604 is verifying that the internal disulfide bridge is properly oxidized and that truncated solid-phase synthesis sequences have been removed. Without high-performance liquid chromatography (HPLC-UV) and mass spectrometry (LC-MS), an unverified vial can contain linear uncyclized fragments or residual trifluoroacetic acid (TFA).
Our top-rated U.S. research supplier, Oath Research (AOD9604) (49/50, Grade A Recommended on RealPeptidesScores), publishes batch-specific certificates from independent third-party laboratory Freedom Diagnostics confirming HPLC-UV purity, LC-MS molecular mass identity, and net peptide content, and cites USP <85> as its endotoxin standard. Across more than 500 batches tested in its certificate archive, Oath maintains a 99.64% average purity over the trailing twelve months.